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Deep brain stimulation (DBS) has become a treatment for a growing number of neurological and psychiatric disorders, especially
for therapy-refractory Parkinson’s disease (PD). However, not all of the symptoms of PD are suﬃciently improved in all
patients, and side eﬀects may occur. Further progress depends on a deeper insight into the mechanisms of action of DBS in
the context of disturbed brain circuits. For this, optimized animal models have to be developed. We review not only charge
transfer mechanisms at the electrode/tissue interface and strategies to increase the stimulation’s energy-eﬃciency but also the
electrochemical, electrophysiological, biochemical and functional eﬀects of DBS. We introduce a hemi-Parkinsonian rat model
for long-term experiments with chronically instrumented rats carrying a backpack stimulator and implanted platinum/iridium
electrodes. This model is suitable for (1) elucidating the electrochemical processes at the electrode/tissue interface, (2) analyzing
the molecular, cellular and behavioral stimulation eﬀects, (3) testing new target regions for DBS, (4) screening for potential
neuroprotective DBS eﬀects,and(5)improvingtheeﬃcacyandsafetyofthemethod. An outlookis givenon further developments
of experimental DBS, including the use of transgenic animals and the testing of closed-loop systems for the direct on-demand
application of electric stimulation.
1.Introduction
1.1. History. One of the well-established therapeutic inter-
ventions in neurological and psychiatric disorders, especially
in the late stages, is the high frequency electrical stimulation
of neuronal structures in the depth of the brain, named by
convention“deepbrainstimulation(DBS)”.Thismethodhas
developed from diﬀerent lines of experimental and clinical
investigations and technical innovations:
(1) stereotactic surgery,
(2) ablativebrain surgery withtissue excision,thermoco-
agulation or cryolesioning,
(3) portable and implantable cardiac pacemakers.
The ﬁrst experiments with stereotactic interventions in
the brain date back to the 1920s when Hess in Zurich
stereotactically implanted depth electrodes in freely moving
cats. In the 1940s, Spiegel et al. in Philadelphia performed
the ﬁrst stereotactical operations in the human brain [1].
The pioneers of ablative brain surgery were Moniz and
Scoville. Both were so-called psychosurgeons who tried
to treat psychiatric disorders, mainly schizophrenia, by
excising or destroying certain brain areas. Their method
went through its ups and downs with the climax being the
subsequently obsolete prefrontal leucotomy in the 1930s.
However, thalamotomy, pallidotomy, lobectomy, cordotomy,
dentatomy,andotherablativeoperationswerealsoappliedto
treat movement disorders, pain, and epilepsy. For example,2 Parkinson’s Disease
in the 1950s, Hassler et al. [2] performed more than 300
stereotactic operations in patients with movement disorders,
such as athetosis, torsion dystonia, tremor, and PD. They
applied the coagulation of various subcortical, mainly pal-
lidal and thalamic, structures and included acute electric
stimulation with diﬀerent pulse shapes and frequency to
ensure an exact location of the electrode tip. Thereby,
they found a clear target and frequency dependence of the
stimulation eﬀect on tremor, hyperkinesias, and rigidity. For
example, stimulation of the inner pallidum with frequencies
up to 10Hz increased the tremor, but stimulation with
frequenciesfrom25 to100Hz decreased thetremor. With the
improvement of surgical techniques and the introduction of
implantable pulse generators (Medtronic, Minneapolis, MN,
USA)in the 1950s, ablative surgery became a chronic electri-
cal stimulation treatment, and DBS was born. Milestones of
its application in central disorders were the therapeutic trials
for the treatment of the following:
(1) pain and epilepsy by Bechtereva et al. in Leningrad
[3],
(2) torticollis spasmodicus by Mundinger in Freiburg
[4],
(3) dyskinesia by Siegfried et al. in Zurich [5],
(4) essential tremorand PD byBenabidetal.inGrenoble
[6].
Despite the rapidly increasing application of DBS in
clinical practice, its mechanisms of action remain poorly
understood. Technical improvements and parameter opti-
mization depend mainly on an empiric trial-and-error strat-
egy. However, the electric stimulation of neurons aﬀected
by DBS acts according to the general rule of excitabil-
ity, that is, according to an exponential strength-duration
relationship [7]. Two major parameters characterize this
relationship. These parameters were ﬁrst deﬁned 100 years
ago by Lapicque to facilitate the comparison of excitability
(excitation thresholds) between diﬀerent objects [8]. The
parameters are “rheobase” and “chronaxie”, which are coor-
dinates on the strength-duration curve for a stimulus. In
neurons, the rheobase is the minimal current amplitude of
an almost inﬁnite duration that triggers an action potential,
whereas chronaxie represents the shortest duration of an
electrical stimulus having an amplitude equal to twice the
minimum amplitude required for excitation. Therefore, the
rheobase is half the current that needs to be applied for the
duration of chronaxie.
1.2.CurrentClinical Application. The spectrumofneuropsy-
chiatricdiseasestreatedbyDBS,eitherroutinelyorinclinical
studies, has expanded very rapidly (for review, see [9–13]).
However, only the following 4 indications are approved for
treatment with DBS by FDA/CE certiﬁcation:
(1) essential tremor with stimulation of the ventrointer-
mediate (VIM) thalamic nucleus [14],
(2) PD with stimulation of the subthalamic nucleus
(STN) or the globus pallidus internus (GPi), a region
that is analogous to the entopeduncular nucleus(EP)
of the rat [15],
(3) dystonia with stimulation of the GPi for torticollis
spasmodicus and generalized dystonia [16],
(4) treatment-resistant obsessive-compulsive disorder
(OCD) with stimulation of the internal capsule
anterior limb [17].
For the extension of approved indications for DBS, it is
necessary to do the following:
(1) to deﬁne new target regions for speciﬁc indications,
(2) to optimize electrodes and stimulation parameters
for speciﬁc target regions.
The largely unsolved questions regarding clinical DBS
are the exact mechanisms of action of the method and
the guidelines for the selection of optimal electrodes and
optimalstimulationparameters. Theoverallaimistoachieve
maximum therapeutic eﬃcacy with a minimum of adverse
side eﬀects and energy draw. This requires basic studies
under deﬁned and reproducible conditions with repeated
access to tissue samples in the neighborhood of the electrode
tip, which can only be realized in animal model systems.
Because PD occurs worldwide and it is the most frequent
degenerative movement disorder, experimental investiga-
tions have focused on animal models of this disease [18].
These models have been most commonly established in
rodents.
1.3. Animal Models. Animal models for the study of the
pathogenetic mechanisms and new therapies for human
movement disorders and psychiatric diseases, such as OCD,
have traditionally been induced by neurotoxins, acting
selectively on neurons aﬀected by human diseases. Examples
of the most common toxic models for the study of DBS are
the following:
(1) the hemi-PD-like disorder induced in rats or mice
by unilateral intracerebral injection of 6-hydroxy-
dopamine (6-OHDA) [19]o rac a r o t i dM P T Pi n j e c -
tion in primates [20],
(2) the PD-like disorder induced by an intravenous
injection of 1-methyl-4-phenyl-1,2,3,6-tetrahydro-
pyridine (MPTP) in mice or primates [21, 22],
(3) the essential tremor-like disease by the intraperi-
toneal injection of the monoaminooxidase (MAO)-A
inhibitor, harmaline, in mice [23, 24],
(4) an OCD-like disease induced by the subcutaneous
injection of quinpirole in rats [25–29].
This paper focuses on optimization strategies for DBS
using the 6-OHDA-induced hemi-Parkinsonism model in
rats; this animal model has several advantages.
(1) The neurotoxin 6-OHDA exerts high selectivity for
dopaminergic neurons, which are destroyed by reac-
tive oxygen mechanisms in the substantia nigra pars
compacta (SNc) either after a direct injection ofParkinson’s Disease 3
the toxin into this structure or after its retrograde
transport from injected dopaminergic projections in
the medial forebrain bundle (MFB) or the striatum
(caudate putamen (CPu) of the rat) to the soma
in the SNc. Therefore, a central pathophysiological
feature of human PD, the selective dopaminergic
denervation of the striatum, is reproduced resulting
in similar electromyographic and gait abnormalities
seen in PD patients [30–33].
(2) This model is the most widely used paradigm for
PD research and is exceedingly well characterized on
the molecular biological, histological and functional
level. It allows for a direct comparison of data with
the majority of experimental PD studies worldwide.
(3) The therapeutic eﬀects of DBS on the core symptoms
of PD, such as rigidity, hypokinesia, tremor, postural
instability, and cognitive impairment, can easily be
monitored using a broad spectrum of behavioral
tests that can analyze single and complex motor and
cognitive functions by investigating a wide variety of
behaviors including the following:
(i) drug-induced rotation,
(ii) accelerated rotation on a treadmill,
(iii) ladder rung walking,
(iv) beam balance,
(v) postural balance,
(vi) asymmetric limb use in a transparent cylinder,
(vii) stepping movement,
(viii) lateralized response in a corridor task test,
(ix) free explorative movement in an open ﬁeld,
radial maze, and water maze,
(x) vibrissae-elicited forelimb placing,
(xi) paw reaching or pellet grasping on a staircase,
(xii) attention and impulsivity in a 5-choice serial
reaction time recorder.
For details of the 6-OHDA-induced hemi-Parkinsonism
model and other relevant animal models of PD, see [34].
To create an optimal experimental design for animal
studies and to avoid unnecessary animal experiments with
DBS, computational simulation and modeling possess great
potential. In silico calculations allow for the prediction
of inﬂuences of DBS parameter changes on electric ﬁeld
properties with increasing precision, the consequences of
electrochemical processes at the interface between the elec-
trodes and surrounding nervous tissue and electrical nerve
cell activity.
2.NumericalAnalysis ofElectricFieldEffects
To understand the eﬀects of DBS, the question of its
mechanism can be addressed at the cellular level by asking
what structures are actually being stimulated or inhibited,
axons, or cell bodies. This question has already been debated
at the time when DBS has ﬁrst been applied in the clinic
[35]. However, only long after the ﬁrst successful application
o fD B Si np a t i e n t st h i sq u e s t i o nb e c a m eas u b j e c to f
numerical analysis using ﬁnite element modeling [36, 37].
The numerical analysis of electric ﬁeld eﬀects aims at
describing the distributionof thestimulated neuronsaround
the DBS electrode based on the inhomogeneous current
density and ﬁeld distributions in the stimulated brain tissue.
The induced transmembrane potential and, alternatively,
the so-called “activation function”, are considered the major
determinants for neuronal stimulation [38, 39]. A correct
description of the distributions of both parameters calls
for the invocation of the inﬂuence of inhomogeneous and
anisotropic brain tissue properties [40, 41]. Anisotropies
and inhomogeneities at the structural level are introduced
by ionic conductivity and the permittivity patterns in the
brain tissue. It can be assumed that membrane structures
inﬂuence these properties in diﬀerent ways. Although ion
currents will mainly ﬂow in parallel to membrane planes,
displacement (capacitive) currents may ﬂow perpendicularly
to bridge membranes because of the high area-speciﬁc
capacitance of these thin layers. Nevertheless, capacitive
membrane bridging will probably play a signiﬁcant role
only in the high-frequency components of DBS pulses
above 10kHz [42]. For this reason, it seems justiﬁed to
consider the anisotropic properties only for ionic currents.
Because such properties are hard to obtain, global brain
data for the anisotropy of water diﬀusion obtained from
NMR measurements are used to describe the anisotropy
of brain tissue [41]. Nevertheless, the frequency-dependent
spreading of the stimulation signal in the brain tissue at the
cellular level is not easy to describe. Such models require
the correct description of cellular geometries and exist for
tissues with a much simpler structure, such as the skin [43].
The electrochemical electrode properties, cell membranes,
cytoplasmic structures and interstitial media form frequency
ﬁlters that change the amplitude and frequency spectrum in
the stimulated tissue depending on the electrode distance.
Thesepropertiesandtheanisotropicpropertiesatthecellular
level are usually not considered, mainly because of the
diﬀerences in the size of the cells and the DBS electrodes.
Nevertheless, a major challenge for the transformation of
human stimulation conditions into animal models is caused
by this size diﬀerence. The size inﬂuences the maximally
applicable voltage (or current) at which membrane poration
and tissue damage are still avoided [44, 45]. In the following
discussion, the major relationships of this limiting DBS
parameter to the electrode size, medium conductivity, cell
constant, and the local shape of the stimulation electrode are
considered.
For a cubical cell conﬁned by two square electrodes, the
resistance, R,isgivenby Ohm’slaw when electrode eﬀectsare
neglected
R =
U
I
=
dE
I
=
dE
iA
,( 1 )
where U, I, d, E,a n di stand for the voltage across the cell,
the current through the cell, the electrode distance and area
(A = d2), and the current density in A/m2, respectively.4 Parkinson’s Disease
(Please note that the vectorial properties of the parameters
are neglected for simplicity.) The resistance can also be
expressed by the cell geometry and the speciﬁc conductivity,
σ
R =
d
σA
=
1
σγ
,( 2 )
with γ = d being the cell constant of the cubical cell, that
is, the geometry factor relating the electrode impedance to
the speciﬁc medium conductivity, σ.A l t h o u g hγ has been
derived for a cubical chamber, it can easily be generalized to
any cell geometry when medium anisotropies and electrode
processes are neglected [39]. Combining (1)a n d( 2), we get
the general relationship of ﬁeld strength and current density
in a homogeneous medium
E =
i
σ
. (3)
In the following discussion, a spherical electrode suspended
in an homogeneous medium of conductivity σ will be
considered. This model correctly describes the inﬂuence
of electrode size on the cell constant, γ, and the interre-
lationships of the applied voltage, electrode current, ﬁeld
strength, and current density at the electrode surface and the
distributionoftheseparametersinthesurroundingmedium.
The resistance of a setup with two concentric spherical
electrodes of distance x is (Figure 1)
R =
rcnt −rel
4πσrcntrel
=
x
4πσ(rel + x)rel
,( 4 )
where rcnt and rel are the radii of the counter- and the inner
electrodes, respectively. The two limiting cases of this model
are two electrodes with comparable radii, that is, electrode
areas of A = 4πr2
el leading to (compare to (2))
R(rcnt≈rel) =
x
4πσr2
el
=
x
σA
,( 5 )
and a counterelectrode at an inﬁnite distance. We obtain
Rx→∝ =
1
4πσrel
=
1
σγ
,( 6 )
with the cell constant of γ = 4πrel for a spherical electrode.
This situation is comparable to a unipolar stimulation with
the counterelectrode being located in the stimulator case.
Applying Ohm’s law to (6), expressing the electrode
current by the current density at the electrode’s surface and
using (3)l e a d st o
Rx→∝ =
1
4πσrel
=
U
4πielr2
el
=
U
4πσEr2
el
. (7)
For the ﬁeld strength at the surface of the electrode E0,w e
obtain:
E0 =
U
rel
=
RI
rel
=
I
4πσr2
el
=
i0
σ
. (8)
σ
rel
rcnt
Figure 1: Distribution of the electric ﬁeld between two concentric
spherical electrodes. Electric ﬁeld lines span the distance between
thestimulationelectrode ofradiusrel andthecounterelectrode with
radius rcnt. The medium between the electrodes has a conductivity
of σ.
Expressing I by the current density at the electrode surface,
we obtain (3). The ﬁeld strength at distance x from the
electrode is
E(x) =
relU
(rel + x)
2 =
I
4πσ(rel + x)
2. (9)
Equation (8) shows that not only the voltage or current
applied to an electrode but also its surface curvature
determines the medium ﬁeld strength. Assuming that ﬁeld
strength, cell size, and orientation determine the induced
transmembrane potential, which is one of the possible
determinants of neuronal stimulation, (8)a n d( 9)i m p l ya
number of conclusions.
(i) Induced transmembrane potentials above approxi-
mately 1V, which are believed to cause membrane
poration and cell damage, may occur especially at
small electrodes.
(ii) Nerve tissue in the vicinity of high electrode curva-
tures, that is, blunt electrode edges, and the like, is
especially vulnerable to electric cell damage.
(iii) Assuming that the redox-like processes at the elec-
trode surfaces generate a constant voltage (overpo-
tentials, see [42]) at the electrode-medium inter-
face, the voltage portion required to overcome the
overpotentials increases for smaller electrodes. This
makes smaller electrodes more vulnerable to the
precision of electrode machining, that is, electrode
size, metal burs, and the like. Assuming that neurons
are stimulated by induced transmembrane potentials
in a range from 5 to 500mV, a linear dependence
of the induced transmembrane potential on the ﬁeld
strength [44, 45] suggests a reach of 10 rel into the
tissue.
(iv) Analysis of the inhomogeneous current density dis-
tributions at the electrode surfaces allows for the
localization of probable hot spots of metal corrosion
and the erosion of the insulating parts.
Numerical calculations of electric potentials, electric
ﬁelds, and current densities around DBS electrodes can beParkinson’s Disease 5
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Figure 2: Electrode placement in a brain slice of a rat at bregma:
−3.60mm/interaural: 5.40mm illustrating that the insulated elec-
trodeshaftpenetrates severallayersofdiﬀerentdielectric properties,
thatis,thescalp,boneofskull,dura mater,subarachnoidspace, and
brain tissue. For unipolar lead electrodes, the counter electrode is
placed subcutaneously directly on the skull at a distance of more
than20mm.The red structure at the tip of the electrode is theSTN.
performed when dimensions and electric properties of the
tissues that surround the electrodes are taken into account.
Figure 2 shows a schematic frontal view of a brain slice of a
rat, where a DBS electrode is placed in the STN.
A simpliﬁed numerical model for a unipolar DBS
electrode in this brain slice is depicted in Figure 3.I t
features the major geometric properties of a rat head as
shown in Figure 2.F i g u r e3(a) speciﬁes the dimensions
of the model on which numerical calculations with COM-
SOL based. We diﬀerentiated between high density/low
conductivity tissue, that is, bone of skull, dura mater
and arachnoid, and low density/high conductivity tissue
and ﬂuids, that is, pia mater, gray and white matter, and
cerebrospinal ﬂuid, which have diﬀerent electric properties.
Because of a lack of data on dielectric properties of rat
tissues, the properties of the respective human tissues were
assumed at a frequency of 130Hz for the simulation in
COMSOL. The rectangular DBS stimulation pulse can be
modeled by a Fourier series with a basic frequency of
130Hz. Because the Fourier coeﬃcients of the signal are
reduced for frequencies above 3kHz, Table 1 contains values
for 130Hz, 1kHz, and 3kHz ([42]; for reference val-
ues see: http://niremf.ifac.cnr.it/tissprop/htmlclie/htmlclie
.htm#atsftag). Figure 3(b) shows the calculated potential
distribution around a stimulation electrode for use in a rat
model (see Figure 8) across this brain model for an input
voltage of 1V.
Figure3(b)demonstrates that thepotential rapidly drops
intheimmediatevicinityoftheelectrodetip.Pleasenotethat
there is a potential drop at the interface between brain and
bone which ishardly visible atthis resolution.Figure4 shows
the calculated distributions of electric potential, electric
ﬁeld, and current density around a cylindrical unipolar DBS
electrode tip.
Figure 5 presents the comparison of simulated poten-
tial distributions between a cylindrical unipolar electrode
(radius: 100μm; see Figure 8) and a spherical unipolar
electrode according to Figure 1 with the counterelectrode at
an inﬁnite distance. For a high consistency of the analytical
and the numerical results and to reproduce the potential
distribution around the cylindrical electrode at a distance
of 400μm, the center of the spherical electrode had to be
positioned in the base of the cylinder and its radius had
to be adjusted to ∼86.6μm. The comparison suggests that
the presented analytical solution for a unipolar spherical
electrode can be used for estimating the ﬁeld and potential
distributions around a stimulating electrode.
Numerical analyses have become very sophisticated in
that they nowadays couple ﬁnite element models of the
electrodes and surrounding medium with cable models of
myelinated axons to predict the volume of activated tissue as
a function of stimulation parameter settings and electrode
design [46]. The combination of numerical modeling and
experimental characterization of the voltage distribution
generated by DBS in the brain provides information on
the quality of the models regarding spatial and temporal
characteristics of the voltage distribution generated by
DBS electrodes [47]. By increasing the complexity of the
model from an electrostatic, homogenous, and isotropic
model to one that explicitly incorporates the voltage drop
and capacitance of the electrode-electrolyte interface, tissue
encapsulation of the electrode, and diﬀusion-tensor-based
3D-tissue anisotropy and inhomogeneity (see Section 3),
it has been shown that the simpler models substan-
tially overestimate the spatial extent of neural activation
[48].
3.ElectrochemicalConsiderationsin
the Contextof DBS
Electrode processes are inherent when applying an electric
ﬁeld via a metal electrode in contact to an electrolyte-
containing medium such as brain tissue. Electrochemists
have been dealing with the properties of electrodes and
electrodeprocessesbeginning inthe19thcentury[49].Com-
prehensive overviews are given in textbooks, for example,
Vetter [50] and Atkins [51]. Serious consideration should be
given to the choice of electrode materials and stimulation
parameters in experimental animal models of DBS. As
described above, simply downscaling electrodes designed for
use in humans to the size of animal brains is not possible.
Most reports on the postmortem analyses of tissue integrity
do not ﬁnd signs of tissue damage after continuous DBS
application in patients [52–54]. However, a newer report
demonstrates histological alterations induced by electrode
implantation and electrical stimulation [55].6 Parkinson’s Disease
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Figure 3: COMSOL simulation.(a) Tissue layers anddimensions forthe COMSOLcalculation around a DBS electrode (radius: 100μm;see
Figure 8) in the STN of a rat brain using dimensionsdepicted in Figure 2. Tissues of similardielectric properties are summarized by arrows.
(b) COMSOL simulationof electric potential in the cross-section depicted in (a). For simplicity reasons, the values of gray matter at 130Hz
from Table 1 were used for the tissue assumed as “brain”.
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Figure 4: Numerical calculations of (a) the electric potential, (b) the electric ﬁeld and (c) the current density around a cylindrical unipolar
electrode (radius: 100μm; see Figure 8) in the STN for an input voltage of 1V.Parkinson’s Disease 7
Table 1: Dielectric properties of human tissues relevant to numerical simulationsof DBS at diﬀerent frequencies.
Tissue
At 130Hz At 1 kHz At 3kHz
Conductivity
(S/m)
Relative
permittivity
Conductivity
(S/m)
Relative
permittivity
Conductivity
(S/m)
Relative
permittivity
Brain gray matter 0.0915 2463000 0.0988 164060 0.10565 66831
Brain white matter 0.0590 1069500 0.0626 69811 0.0650 30133
Cerebrospinal ﬂuid 2 109 2 109 2 109
Dura 0.5006 15276 0.5008 5344 0.5010 2360
Skull bone 0.0201 5355 0.0202 2702 0.0203 1246
Scalp 0.0005 42909 0.0007 32135 0.0009 30569
1
1 1
0.9
0.8
0.7
0.6
0.5
0.5 0.5
0.4
0.4 0.4
0.3
r r
Figure 5: Simulated potential distributions of spherical (r ∼
86.6μm, cell constant γ = 1.09mm) and cylindrical (r = 100μm,
cell constant γ = 1.00mm) electrodes.
In contrast, experimental DBS in rat models has often
been accompanied by tissue damage, especially during long-
term stimulation [56]. This might be the reason why
many studies on DBS in rats were restricted to short-term
stimulation. However, a recent study showed that tissue
damage may also occur during short-term stimulation [57].
These contrasting ﬁndings in animals and patients may
have various underlying reasons, such as smaller electrode
size and blunt edges (higher curvatures), which both result
in high ﬁeld strengths in the vicinity of the electrodes and
in higher local current densities leading to more intense
local electrode reactions. Electrode reactions and the use of
less inert electrode materials, for example, nonnoble metals,
result in potentially toxic products, including denatured
proteins, gas, dissolved metal ions, and erosion products of
the insulating materials. Electrochemical reactions due to
energy dissipation at the interface of stimulation electrodes
to the surrounding tissue are unavoidable [42]. The degree
of tissue damage is determined by the electrode materials.
Nonnoble metals, such as stainless steel, may deposit iron
ions in the tissue [57]. Metal ions are a potential source of
protein-denaturation and the formation of new antigenic
determinants leading to immune reactions [58]. Iron is
especially known for its cytotoxicity [59]. The degradation
of organic compounds and the evolution of gas, such
as hydrogen and chlorine, are nonphysiological processes
that change the properties of the extracellular ﬂuid. These
changes cause neuronal damage [60].
There are a number of parameters that have to be
considered when applying electric ﬁelds in living tissue. One
problem is that no ideally nonpolarizable electrodes, that is,
electrodes of the 2nd kind, can be used under experimental
or clinical stimulation conditions [42, 51, 61]. Polarizability
is the reason for overpotentials. The shape, that is, the
amplitudes of the Fourier components of the applied signal,
determines the overpotentials that are dissipated in electrode
processes (see below). Although electrodes for human use
are driven in a constant-voltage mode, constant-current
stimulation with square-topped ﬁelds is typically used in
animal models (Figure 6). In constant-current mode, the
electrodes are driven by a voltage function that corrects
for energy dissipation by electrode processes [62]. A very
important parameter inﬂuencing stimulation eﬃciency is
the impedance of the tissue surrounding the electrode.
This impedance changes shortly after electrode implantation
and over time. An electrically insulating glial sheath forms
around the stimulation electrodes in patients [52, 63]a n d
in laboratory animals [64]. This sheath is presumably
responsible for the increase of electrode impedance after
DBS surgery [65, 66]. Finite element models have identiﬁed
the thickness and conductivity of the encapsulation layer
around the electrode contact and the conductivity of the
bulk tissue medium as the main determinants of altered
electrode impedance and found an approximately 50%
reductionin the volume ofactivated tissue using typicalDBS
settings [67].However, one study reported a time-dependent
decrease of impedance after DBS surgery [68]. Recently,
a glial cell culture system has been developed to model
the impedance changes after electrode implantation [69].
Because electrode impedance is highly frequency dependent,
changes in stimulation parameters that result in a change
in the Fourier content may result in changes in stimulation
eﬃciency [42, 61].
The rectangular stimulation pulse in Figure 6,a si ti s
used in animals, is comprised of its basic frequency and
higher harmonic frequencies, that is, its Fourier content
[42]. Thus, if we assume a smooth function for the
frequency dependence of the impedance for the harmonic,
low amplitude signals, the impedance for every frequency
can be calculated from Ohm’s law applied to the voltage
and current values. Accordingly, it should be possible to
calculate the eﬀective electrode impedance from the RMS
values of voltage and current for a pulse signal that contains
a Fourier spectrum of frequencies. Nevertheless, even for
a harmonic signal, the impedance depends on the signal8 Parkinson’s Disease
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500μA
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Figure 6: Stimulation pulse as commonly used in the rat
model. Please note that the negative stimulation pulse is charge-
compensated by the subthreshold positive current between stimu-
lation pulses.
amplitude at every given frequency. Moreover, the charge-
carrier transition from electronic currents in the electrode
metal to the ionic current in the medium will lead to a
nonlinear current voltage relationship and the generation
of harmonic frequencies [70]. These complex electrode
properties are usually described to include a constant-phase
element (CPE; see [42]).
Models to describe this nonlinearity include redox
processesrequiringacertainactivationenergyforthecharge-
carrier transitions and electrochemical reactions, which are
summarized under “overpotentials”. An additional problem
arises from the fact that the nonlinear current transfer
function at a given frequency and electrode site (e.g., with a
certain curvature) will be inﬂuenced by the current induced
by the other harmonics or a DC-oﬀset; that is, these currents
may contribute to the activation energy required for the
charge-carrier transitions at the frequency considered.
In principle, these interrelationships have to be
accounted for in models that aim at calculating optimum
stimulation parameters that are tailored to the individual
patient. Although the situation is not as complicated for the
larger electrodes used in humans, which avoid blunt edges
and the approach is welladvanced [48], there is too little
information on all of the necessary parameters in animal
models ofDBSwhere the nonlinear electrode properties play
a stronger role (see above).
4.EffectsofExperimentalDBS on
NeuronalActivity
Originally, DBS was seen as a functional ablation because
of the similarity of its clinical eﬀect to surgical ablation,
which suppresses or inhibits the stimulated nucleus. Several
neuronal mechanisms of inhibition at the site of and
more remote from DBS have been considered. First, direct
eﬀects occur as a result of the ﬁeld application to the
neural membrane and result in regions of depolarization
and hyperpolarization along each neural process [71, 72].
Therewith, DBS induces alterations in somatic voltage-gated
currentsthatconcertedlyblockneuraloutputattheelectrode
(depolarization block). In particular, the persistent Na+
current (INaP) is fully blocked, the Ca2+-mediated responses
are strongly reduced, suggesting a T- and L-type Ca2+
current depression, whereas the hyperpolarization-activated
cationic current (Ih)i sn o ta ﬀected [73]. However, DBS
may hyperpolarize local neuronal cell bodies and dendrites
directly [37, 72] or indirectly, given the elevated extracellular
K+ levels in experimental Parkinsonism [74], which might
interfere with normalactivity andgenerateabnormalactivity
in neural networks [75]. Second, DBS may elicit indirect
eﬀects by activating axon terminals that make synaptic
connections with neurons near the stimulating electrode
(synaptic inhibition). Experimental and modeling results
have shown that aﬀerent inputs have a low threshold for
activation during extracellular stimulation [76–80]. Given
the large predominance of inhibitory presynaptic terminals
in the STN and GPi, their release could locally reduce
neuronal activity [81]. Indeed, in vivo [79, 82–86]a n din
vitro [73,87–89]neural recordings in thestimulatednucleus
show decreased activity during and/orafter DBS.In contrast,
this ﬁnding was not conﬁrmed recently by microelectrode
recordings in human STN when stimulation was delivered
via an actual DBS macroelectrode [90]. Third, on a systemic
level, the synaptic transmission of the eﬀerent output of
stimulated neurons may fail as a result of transmitter
depletion, which results in synaptic depression or functional
deaﬀerentiation [91, 92].
However, evidence is accumulating for the activation
(excitation) of the DBS-stimulated nucleus with subsequent
transmission throughoutthenetwork. Whencomputeralgo-
rithms are used toremove stimulusartifacts, DBSoftheSTN
in primates increases activity in the GPi during stimulation
[93].Inturn,thismayinducethemodulationofpathological
activity in the whole network [94]. Recordings from the
eﬀerent target nuclei provide the most pertinent neural data
on the eﬀects of DBS. In contrast to the above-mentioned
studies, in vivo recordings in eﬀerent nuclei indicate that the
output of the stimulated nuclei is increased by DBS [95–97].
This is possible despite somatic inhibition because action
potential initiation from extracellular stimulation occurs in
the axon [72, 98]. In general, cathodic stimuli generate
membrane depolarization in regions near the electrode
and membrane hyperpolarization in regions that ﬂank the
region of depolarization. The ﬁrst few nodes of Ranvier
are typically depolarized by the stimulus pulse because of
the short internodal spacing of the axon compared to the
spatial distribution of the ﬁeld generated by DBS electrodes
[37]. There is also early neurophysiological evidence of the
occurrence of such phenomena [99–101]. The second eﬀect
of extracellular stimulation that supports the decoupling of
activityintheaxonandcellbodyduringDBSistheactivation
of transsynaptic inputs in the close surrounding area of
the soma (see above). In particular, because DBS-induced
action potential initiation occurs in the axon, the eﬀerent
output of neurons suprathreshold for direct activation by
the applied ﬁeld is relatively unaﬀected by the transsynaptic
inhibition, and the majority of local cells within 0.2mm of
the electrode will generate eﬀerent output at the stimulus
frequency when the therapeutic stimulation parameters areParkinson’s Disease 9
used [37]. This “driven”axonal activity replaces spontaneous
intrinsic ﬁring with the exogenously induced patterns [102].
DBS, as an extracellular stimulation, is expected to activate
subsets of both aﬀerent and eﬀerent axons, leading to
antidromic spikes that collide with the ongoing spontaneous
spikes and orthodromic spikes that evoke synaptic responses
in target neurons. The cellular basis of this interaction
between the anti- and orthodromic spikes is unknown,
but this mechanism could converge at the level of the
STN axon initial segment where spontaneous ﬁring in STN
neurons begins [103]. In addition, neurons subthreshold for
direct excitation will exhibit suppression of their intrinsic
ﬁring patterns that are regulated by stimulation-induced
transsynaptic inputs.
It still is a matter of debate regarding which of the
eﬀects of DBS is therapeutically eﬀective and how DBS
alleviates motor symptoms. There are at least three viable
hypotheses. First, pathological GPi activity is inhibited (see
above). Second, STN and GPi DBS induces the regularity
of GPi activity [96], thereby reducing misinformation in
the pathologically noisy GPi signal and abnormal stochastic
resonance[93].DBSmayregularize thepathologicalsynaptic
activity of basal ganglia output structures [104] in addition
to increasing the ﬁring rate of ﬁbers projecting from the
site of stimulation [37, 95, 96, 105]. This regularized GPi
activity may reduce thalamic error rates (a surrogate for
Parkinsonian symptoms) [106]a n di n c r e a s et h eﬁ d e l i t y
of thalamic neurons [107]. This view is experimentally
supported by small changes in GPi ﬁring rates in com-
parison to changes in regularity and bursting activity in
response to DBS [96, 104, 108]. Third, DBS activity induces
resonance ampliﬁcation of the information signals in the
basal ganglia-thalamus-cortex system necessary for normal
movement. Indeed, there are multiple oscillators within this
system at many diﬀerent frequencies, although the main
or average frequency is approximately 130pps [109], and
DBS resonates with normal intrinsic oscillators [110]. Basal
ganglia oscillations in local ﬁeld potentials in the 11–30-
Hz range are antikinetic [7, 111–113]; reductions in STN
oscillations in this frequency range are correlated with
clinical improvement [114, 115], and DBS in this frequency
range worsens motor performance [116, 117]. Oscillations
in the range of 70Hz are thought to be prokinetic because
they are lost in Parkinsonism [7, 113, 118]a n dr e s t o r e db y
levodopa treatment [116, 117].
5.Biochemical and FunctionalDBS Effects
Eﬀects of experimental DBS on neuronal activity are also
reﬂected in changes of neurotransmitter release. Microdial-
ysis studies show an increase in striatal dopamine (DA)
release, an activation of striatal DA metabolism and an
activationofstriataltyrosinehydroxylase(TH)activity[119–
122]. Furthermore, an enhanced glutamate release in the
rat entopeduncular nucleus (EP), the rat analog to the
human GPi, during STN stimulation, indicating a facilitated
activity of the STN during stimulation [105, 123]a n d
an increased GABA release of pallidal origin in the SNr
[124] were demonstrated. These ﬁndings are consistent with
electrophysiological and theoretical data that suggest an
excitation of axons (see Section 4). The described eﬀects
may explain the immediate eﬀects of DBS, such as the
alleviation of tremor by stimulation of the VIM nucleus
of the hypothalamus. However, they cannot readily explain
the delayed eﬀects, such as the reduction of rigidity within
seconds to a few minutes, the alleviation of hypokinesia after
h o u r so rd a y s ,t h ee ﬀect of STN DBS on tremor within
s e c o n d st od a y so rt h ee ﬀect of GPi DBS on dystonia with
a delay of days to weeks. Also, carryover eﬀects can be
observed. For example, hypokinesia returns only slowly after
the cessation of DBS.These clinicalobservations suggest that
electrical stimuli are translated into network reorganization
or eﬀects at the gene expression level.
Gene expression studies indicate that STN DBS may
reverse a 6-OHDA lesion-induced increased expression of
glutamate decarboxylase-(GAD) 67 mRNA in the EP and in
the substantia nigra pars reticulata (SNr) [125]. GAD cat-
alyzes the synthesis of gamma-aminobutyric acid (GABA).
Care should be taken when DBS studies are performed
in healthy animals because the data may not equal those
acquired in Parkinsonian rats. In a microarray study,
mRNAs of synaptic vesicle protein 2b (Sv2b) and ubiquitin-
conjugating enzyme E2B are upregulated by DBS in healthy
rats but downregulated by DBS in lesioned rats [126].
Sv2b is involved in synaptic vesicle exocytosis and thus,
neurotransmitter release [127]. E2B plays a role in DNA
repair [128] and is required for neurite outgrowth [129].
STN DBS, performed for 2h in healthy rats, induced an
increase in striatal TH activity without changes in TH gene
expression determined by a TH activity assay and RT-PCR
analysis [122]. In contrast, a microarray analysis combined
with real-time PCR and immunohistochemistry showed
an upregulation of TH gene expression, but not of TH-
positive neurons or TH-positive ﬁber density, by STN DBS
in 6-OHDA-lesioned rats [126]. Apparently, DBS eﬀects are
altered by an imbalance in the basal ganglia network caused
by a 6-OHDA lesion.
We also found a DBS-induced downregulation of
calcium/calmodulin-dependent protein kinase-type IIA
(CaMKIIa) and Homer1 in 6-OHDA lesioned rats [126].
Both genes are involved in glutamate neurotransmission
[130–132]. In addition, we have found an upregulation
of insulin-like growth factor 2 (IGF2) and insulin-like
growth factor-binding protein 2 (IGFBP2) [126]. As these
molecules play a role in postnatal neurogenesis in the
hippocampus of mice [133] one could speculate that their
upregulationafterDBScouldindicatea reorganization ofthe
basal ganglia circuitry. An expression of immediate−early
genes, for example, c−fos, has been found at the mRNA
level [125]w i t hc−fos being also induced by L−DOPA
treatment in dopamine−denervated marmosets [134]
and by immunohistochemistry [135]a f t e rS T ND B S .T h e
immunohistochemical study demonstrated an upregulation
of c−Fos, c−Jun, and Krox−24 not only in the STN but also
in the projection areas of the STN [135].
Functional studies, however, require animals that are
awake and freely moving. Because of the above-mentioned
methodological problems, the latter studies are scarce.10 Parkinson’s Disease
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Figure 7: Chronic instrumentation of a freelymoving rat. (a) Rat with a portable stimulator in a backpack; (b) stimulator purchased from
the company R¨ uckmann and Arndt, Berlin, Germany. Scale bar in (b): 10 mm.
Darbaky et al. [56] demonstrated an improvement of motor,
but not cognitive, functions in 6-OHDA lesioned rats with
STN DBS using platinum electrodes connected to a stimulus
generator via a swivel. Other studies have found a reversal
of limb-use asymmetry and an improvement in treadmill
locomotionin 6-OHDAlesioned ratsduring STN-DBS[136,
137]. The development of instrumentation for freelymoving
animals, such as an implantable microstimulation system
[64]oracarry-onstimulator(describedherein,seeFigure7),
promises many more data on functional improvements.
Using an implantable microstimulation system, Harnack
et al. [138] demonstrated a preservation of dopaminergic
nigral neurons in a 6-OHDA rat model with progressive
Parkinsonism using chronic STN-DBS.
A role for BDNF is suggested by the results of chronic
(14d) DBS in freely moving 6-OHDA rats, which showed a
protection of SNc neurons, arguing for beneﬁcial functional
eﬀects of DBS in the early phase of PD [139].
6.OptimizationStrategiesfor
ExperimentalDBS
Optimization of DBS aims at (1) achievement of optimum
electric coupling without nerve cell damage (2) adjustment
to the treatment of diﬀerent neurological and psychiatric
diseases by ﬁnding the most eﬀective target and (3) deﬁning
optimum stimulation parameters for the speciﬁc target. This
multivariate testing requires long-term in vivo experiments
in the animal model with (a) the systematic investiga-
tion of DBS eﬀects under various stimulation conditions;
(b)recordingof motor and cognitivefunctions, and (c)anal-
ysisofthenervoustissuein theelectrodeenvironment onthe
cellular and molecular level. A prerequisite for such studies
is the establishment of a disease model with chronically
instrumented freely moving animals. This strategy will
facilitate clinical treatment with highest eﬃcacy and the
lowest adverse side eﬀects.
6.1. Chronic Instrumentation of Freely Moving Animals. The
implementation of an animal model for the research on
movement disorders not only requires adequate tests them-
selves but it also has to allow for the animals to express their
natural locomotor behavior to not dismantle their drive for
motionand tonotchange theirroutines. Inthepast, external
stimulators constrained the animals, because the connecting
cables were easily twisted by rotational movements. Also, the
large appliances ﬁxed to the animal restricted movements.
Thus, such experiments were strongly limited in time. To
date, basically three experimental designs allow for long-
term experiments. First, housing the rat in an open cage and
connecting a cable through the open cage top directly to the
animal allows for most movements although itmay not solve
the rotation problem under all circumstances [139, 140].
Alternatively, animals are housed in cages with open tops
allowing the tubes and cables to be connected to a swivel on
top [141]. The swivel provides the cables with an additional
degree of freedom and can also be set to read the rotation
of the animal. A second option, being most promising
for long-term animal experiments, is the implantation of
the stimulator. This requires a small apparatus with low
weight at the expense of a shorter battery life. Stimulation
parameters can be adjusted from outside of the animal
[64]. As a third option, the animal permanently carries the
whole instrumentation in a backpack (Figure 7). This allows
the device to be signiﬁcantly larger and better accessible
compared totheimplantable device.Also,the batterymay be
exchanged for longer stimulation. In summary, this option
combines the advantages of options 1 and 2, because (1)
the surgical intervention is much less extensive compared
to the implantation of the whole device and (2) the animal
can move without constraints. This improved freely moving
animal model is suitable for measuring classical drug-
induced rotation because problems of the restraining cable
and tube torsion do not arise.
6.2. Electrode Material and Stimulation Parameters. DBS in
rodents requires electrodes that are thinner than those for
humans, but it must be stable enough to pierce through
the tissue without bending to ensure correct electrode place-
ment. In addition to electrochemical problems arising from
these dimensions (see Section 3) stability is an issue limiting
the use of platinum/iridium electrodes for testing diﬀerent
electrode tip shapes or multipolar concentric alignments of
electrodes. However, corrosion followed by tissue damage
occurs when using stainless steel electrodes (see Section 3).
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in many diﬀerent aspects, such as electrode polarity, current
amplitude, and pulse width and frequency, and concerning
the standard algorithms that are commonly used for an
eﬃcientDBSinhumans,wecanthinkaboutthecomparative
testing of several simple electrode designs for experimental
DBS. One design implies a unipolar cathodic DBS-pulse
with a counter electrode underneath the skin for a safe
and simple current application just like the common setting
used for human therapy with Medtronic devices where the
counter electrode is part of the implantable pulse generator
(IPG) case. Such an electrode made from platinum/iridium
is depicted in Figure 8. Alternative settings consist of bipolar
electrodes that can be designed in two diﬀerent ways:
(1) one concentric bipolar electrode with two concentric
contact surfaces, or;
(2) two separate, unipolar electrodes merged together at
a region-speciﬁc distance.
The unipolar stimulation generates a nearly spherical
ﬁeld distribution,whereas bipolarelectrodesproducea more
focused ﬁeld with higher eﬀectsin the space between the two
electrodes, especially close to the electrode tips and edges.
In both cases, the amplitude can be adjusted very precisely
in small intervals in analogy to the Medtronic devices.
With higher amplitudes, the distributed ﬁeld increases and
can aﬀect structures at a distance from the electrodes,
allowing for more neural elements to be stimulated. In
the case of DBS of the STN, this may primarily concern
the zona incerta and substantia nigra. Newly designed
electrodes include sectorial or spot electrodes with a laterally
directed ﬁeld driven in the unipolar or bipolar modes.
Such high-perimeter electrodes may increase the variation
of current density on the electrode surface, decrease power
consumption for the stimulation of axons and reduce the
costs and risks of replacement of depleted stimulators
[142].
Because of the inverse exponential function describing
the interdependence of pulse width and amplitude reﬂected
by the parameters rheobase and chronaxie (see Section 1
for an explanation of these historical items), it is obvious
that with higher current amplitudes (i.e., ﬁeld strength) the
pulse width may be lowered nonetheless exciting the sur-
rounding structures of the electrode suﬃciently. To protect
the treated subject from severe side eﬀects, the stimulation
amplitude has to be set as high as needed to reach the most
beneﬁt but as low as possible not to exceed the threshold
that causes damage by electrochemical reactions and the
unintentional excitation of nontarget structures. Chronaxies
for DBS eﬀects have been estimated to be around 65μsf o r
thalamic and around 75μs for pallidal stimulation [143]. In
STN DBS, pulse width seems to have minor inﬂuence on
the improvement of clinical signs. However, higher pulse
widths can be used successfully in pallidal stimulation or
in the stimulation of thalamic structures, such as the VIM
nucleus.
Although the frequencies of a therapeutic eﬀect of DBS
aremainly found ina rangehigher than 100Hz,thisparame-
terhasalso tobeadjustedforspeciﬁcareas andpathways.For
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Figure 8: Photograph (a) and scheme (b) of a custom-made
unipolar electrode (POLYFIL, Zug, Switzerland) with the pole
made from platinum/iridium (PtIr) for experimental DBS in freely
moving chronically instrumented rats. Scale bar in (a): 5mm.
example,stimulationofthePPNrequiresalowerstimulation
frequency of 20–60Hz [144–150]. Because animal models
should mimic the clinical situation as closely as possible,
we usually apply the human standard of 130Hz for STN
stimulation in the hemi-Parkinsonian rats as a compromise
between power consumption and clinical eﬃcacy, regarding
this parameter as being of minor importance for strategies to
optimize DBS.
6.3. Closed-Loop Systems. One of the major challenges
f o rf u t u r ei m p r o v e m e n t so ft h eD B St e c h n o l o g yi st h e
implementation of feedback modulation in so-called closed-
loop systems involving built-in sensing capabilities. They
were ﬁrst realized for the treatment of epilepsy by taking
advantage of EEG recordings for the controlled delivery
of DBS to the seizure focus. For this purpose, orig-
inally nonimplantable bedside systems have been used,
which are meanwhile substituted by implantable auto-
matic devices, such as the responsive neurostimulator
(RNS) lead system (NeuroPace, Mountain View, CA, USA)
[151–154].
Further progress results from improved stimulation
protocols that aim at desynchronizing the pathological
oscillations of neuronal activity [155]. They require pulse
generators capable of simultaneously recording physiolog-
ical parameters and providing adapted stimuli. Basically,12 Parkinson’s Disease
Table 2: Experimental DBS with indications and target regions under study.
Indication Target region References
Parkinson’s disease, progressive supranuclear palsy Pedunculopontine (PPN) nucleus [144–146,
148, 149]
Tremor types other than essential and Parkinsonian
tremor (Holmes tremor, dystonic tremor, thalamic
tremor, essential writer’s tremor, and neuropathic
tremor)
Ventrointermediate (VIM), ventral oralis (Vo) and anterior and
posterior nucleus thalami,and subthalamic nucleus (STN) [156–159]
Huntington’s disease Globus pallidusinternus and externus (Gpi and Gpe) [160, 161]
Alzheimer’s disease Fornix/hypothalamus [162]
Thalamic pain and poststroke ﬁxed dystonia Posterior limb of internal capsule [163, 164]
Central nociceptive pain syndromes (ischemia,
hemorrhage, multiple sclerosis, spinal cord, and injury) Periaqueductal/periventricular gray matter (PAG/PVG) [165]
Peripheral neuropathic pain (postzoster neuralgia,
radiogenic plexus lesion,phantom pain,
postdissectomy syndrome, chronic radiculopathy, and
carcinoma pain)
Ventroposterolateral/ventroposteromedial (VPL/VPM)nucleus
thalami,ventrocaudal (Vc) nucleus thalami,medial lemniscus,
and PAG/PVG
[165, 166]
Epilepsy
Anterior and centromedian nucleus (AN and CMN) thalami,
mammillary body (MB) hypothalamic and mamillothalamictract,
STN, hippocampus, caudate nucleus (CN), and cerebellum
[167, 168]
Obsessive-compulsive disorder
Anterior limb of internal capsule (ALIC), STN, ventral caudate,
inferior thalamicpeduncle, nucleus accumbens (NAc), and ventral
capsule/ventral striatum (VC/VS)
[25–
29, 169–
171]
Depression Subcallosal cingulated gyrus, inferior thalamic peduncle, NAc,
VC/VS
[29, 172–
174]
Gilles de la Tourette syndrome Centromedian-parafascicular (Cm-Pf) and Vo complex thalami,
Gpi, and NAc [17, 29]
Minimally conscious state Central thalamus [175]
three diﬀerent methods of desynchronizing stimulation with
putative therapeutic impact have been developed:
(1) coordinated reset stimulation,
(2) nonlinear delayed feedback stimulation,
(3) multisite coordinated delayed feedback stimulation
[155].
These methods will ultimately contribute to the opti-
mization of the DBS technology in the clinical practice too.
6.4. Novel Target Regions and Indications. The expanding
spectrum of neuropsychiatric diseases tested for the putative
therapeutic eﬀects of DBS requires a high ﬂexibility of
stimulation parameters. Eﬀorts are also directed toward the
search for suitable target regions. Nevertheless, most of these
eﬀorts follow a trial-and-error strategy. Of special interest,
clinical problems of cognitive impairment and late-stage
PD may be alleviated by DBS with modiﬁed frequencies
and the targeting of the PPN. For example, impaired
working memory is improved by the low-frequency (25Hz)
stimulation of the PPN [176].In severecases of late-stage PD
withposturalinstabilityandfreezingofgait,dualstimulation
of the PPN with 25Hz and of the STN with 60Hz reveals a
higher synergistic eﬀectcompared to STN-DBS or PPN-DBS
alone [177]. The PPN is also targeted to reduce falls [148]
and reaction times during motor tasks in PD [149]. Chronic
low-frequency stimulation (25Hz) of the PPN has been
shown to restore functional connectivity [150]. Interestingly,
a modiﬁcation of DBS, using the dorsal column of the spinal
cord as the target, enables functional recovery in chronic
bilaterally 6-OHDA-lesioned PD rats [178, 179]. However,
this could not be conﬁrmed in initial clinical studies on
PD patients [180]. Application of DBS in the centrum
medianum-parafascicularis(Cm-Pf) complex for patients in
a vegetative state is controversial as patients respond poorly
if at all [181, 182]. A survey of potential candidates for DBS
beyond movement disorders that are already approved for
clinical DBS, such as PD (see Section 1.2) ,i sgi v e ni nT a b l e2.
Notably, the survey by no means claims completeness.
However, future studies will probably reduce the number of
appropriate target regions of DBS for diverse indications.
Therefore, an optimization concerning appropriate targets
for any indication will be achieved.
6.5. Transgenic Disease Models. Drawbacks of the toxic
animal models described in Section 1.3 are diﬀerences in
the genetic background (healthy animals versus genetically
susceptible patients) and in the pathogenetic mechanisms,
whereby the models only partly mirror the pathogenesis
and therapeutic response of the human diseases. In this
situation, the transgenic technology has several advantages.Parkinson’s Disease 13
It provides a potentially unlimited number of animals that
either lack or overexpress genes that have been identiﬁed as
pathogeneticallyrelevant risk genesin humans. Forexample,
by introducing mutated candidate genes, transgenic models
have been generated for the following:
(1) PD with α-synuclein (PARK1 gene) [183],
(2) Huntington’s disease with huntingtin (HTT gene)
[184],
(3) dystonia with torsinA (DYT1 gene) [185].
Of advantage is also the possibility for the exploration
of certain details of the mechanisms of action of DBS using
gene-targeted animals. For example, adenosine A1 receptor-
mutantmice(knockoutornull mice)havecontributedtothe
elucidation of the role of adenosine for the suppression of
essential tremor by DBS [24].
7.Conclusionsand Outlook
Despite new and promising developments in the ﬁeld of
transgenic animal technology, the conventional 6-OHDA
hemi-PD rat model is still suitable for the investigation of
various aspects of experimental DBS, such as the analysis
of electrochemical processes at the electrode/tissue inter-
face and of molecular and cellular changes in the tissue
surrounding the stimulating electrode. For optimization,
new electrode materials and modiﬁed surface structures are
investigated in combination with computational simulation
and numerical electric ﬁeld calculations. Also, new target
regions are tested for eﬀects of DBS on motor and cognitive
functions assessed by speciﬁc behavioral tests. The ﬁnal
aim is the improvement of the eﬃcacy and safety of DBS
in clinical practice. Future investigations will concern the
following issues, among others:
(1) optimization of pulse shape (f-content) to reduce
adverse eﬀects (such as electrode reactions and cell
damage) to the system,
(2) technical improvements with smaller, rechargeable
and sensor-containing DBS devices that enable cur-
rent steering and closed-loop stimulation [154],
(3) desynchronization of pathological oscillatory excita-
tions [155],
(4) a combination of ﬁber optic and optogenetic tech-
nology for the stimulation of selected neuronal
populations [186],
(5) transgenic and primate animal models of movement
disorders for the further elucidation of the mech-
anisms of action of DBS and for the more precise
targeting of speciﬁc cell types by DBS [187],
(6) an individualized combination of therapies of DBS
and medication,
(7) innovations such as microstimulation via brain-
machine interfaces [188] and electrical microarray
implants(NeuroNexusTechnologies, Ann Arbor,MI,
USA), which are being tested in animal models of
human diseases.
These investigations will not only allow for a deeper
insight into DBS mechanisms but also provide signiﬁcant
therapeutic beneﬁt for patients with neuropsychiatric dis-
eases, in particular in movement disorders such as PD [18].
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